Tesofensine (NS 2330)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tesofensine (NS 2330), covering 2013-10-29 to 2013-10-29. Get the full timeline:
Most recent: Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations [Phase 2]